Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

Sort by

  • Default sorting
  • Sort by popularity
  • Sort by newness
  • Sort by price: low to high
  • Sort by price: high to low

View

  • 9 items
  • 15 items
  • 30 items

Showing 10–12 of 12 results

  • 102_Norhydromorphone-Base
    Quick ViewSelect options

    Norhydromorphone Base (CII)

    $575.00 – $2,300.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 14696-23-2 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0989-**
    Quick ViewSelect options
  • 94_8,14-Dihydrooripavine-Base
    Quick ViewSelect options

    8,14-Dihydrooripavine Base (CII)

    $575.00 – $2,300.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Impurity <span style="color: #000000;"><strong>CAS#</strong></span> 873087-79-7 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0083-**
    Quick ViewSelect options
  • 83_Hydromorphone-Hydrochloride
    Quick ViewSelect options

    Hydromorphone Hydrochloride (CII)

    $173.00 – $3,460.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 71-68-1 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-0057-**
    Quick ViewSelect options
  • 1
  • 2

Recent Articles

  • The Security of Onshore Manufacturing
  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate